https://www.selleckchem.com/products/brd0539.html
n with metastatic or nonmetastatic CRPC who progress despite CAB with bicalutamide + ADT. First-line AAT with enzalutamide + ADT provided a significant improvement in time to PSA progression versus flutamide + ADT. Enzalutamide + ADT may therefore be the preferred first-line AAT option in Japanese men with metastatic or nonmetastatic CRPC who progress despite CAB with bicalutamide + ADT. Due to increased risk of pyelonephritis, patients with intestinal reconstruction of the lower urinary tract (IRLUT) have long been advised against kidn
Like
Comment
Share
